Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a chronic condition that affects one in six adults in the US during their lifetime. The current practice of antidepressant medication prescription is a trial-and-error process. Additionally, over a third of patients with MDD fail to respond to two or more antidepressant treatments. There are no valid clinical markers to personalize currently available antidepressant medications, all of which have similar mechanisms targeting monoamine neurotransmission. The goal of this review is to summarize the recent findings of immune dysfunction in patients with MDD, the utility of inflammatory markers to personalize treatment selection, and the potential of targeting inflammation to develop novel antidepressant treatments. To personalize antidepressant prescription, a c-reactive protein (CRP)-matched treatment assignment can be rapidly implemented in clinical practice with point-of-care fingerstick tests. With this approach, 4.5 patients need to be treated for 1 additional remission as compared to a CRP-mismatched treatment assignment. Anti-cytokine treatments may be effective as novel antidepressants. Monoclonal antibodies against proinflammatory cytokines, such as interleukin 6, interleukin 17, and tumor necrosis factor α, have demonstrated antidepressant effects in patients with chronic inflammatory conditions who report significant depressive symptoms. Additional novel antidepressant strategies targeting inflammation include pharmaceutical agents that block the effect of systemic inflammation on the central nervous system. In conclusion, inflammatory markers offer the potential not only to personalize antidepressant prescription but also to guide the development of novel mechanistically-guided antidepressant treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., Sanislow, C., & Wang, P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091379 · Cited by 7,067 · cited 1×
“The National Institute of Mental Health has launched the Research Domain Criteria (RDoC) initiative to promote novel objective ways for conceptualizing and classifying mental disorders [31].”
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationA Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942 · cited 1×
“Several lines of investigation implicate inflammation in the pathophysiology of depression in a sub-group of patients with MDD [32,33].”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“Large community trials such as the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial have shown that less than a third of patients adequately respond to the initial antidepressant medication trial [25].”
BackgroundResultSelf-citationC-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
(2010) · The Lancet · doi:10.1016/s0140-6736(09)61717-7 · Cited by 2,546 · cited 1×
“Chronic low-grade systemic inflammation is associated with elevated CRP levels, which in turn have been associated with increased mortality (both vascular and non-vascular) and a higher likelihood of cardiovascular disease and ischemic stroke [39].”
BackgroundSlavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 1×
“Increased BBB permeability is associated with infiltration of immune cells, which in turn have been shown to promote depressive behavior [60,68].”
BackgroundHasin, D. S., Goodwin, R. D., Stinson, F. S., & Grant, B. F. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1097 · Cited by 1,645
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 2×
“While there was no overall difference between infliximab and placebo, in post hoc analyses they found that in a subgroup of TRD patients with CRP ≥ 5 mg/L, infliximab was superior to the placebo in the improvement of depressive symptom severity [97].”
BackgroundResultPeripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies
Köhler, C. A., Freitas, T. H., Maes, M., de Andrade, N. Q., Liu, C. S., Fernandes, B. S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., et al. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12698 · Cited by 1,443 · cited 1×
“While one study has previously reported higher levels of Th17 cells and lower regulatory T cells in peripheral circulation, along with higher levels of RORγT mRNA in peripheral blood lymphocytes of depressed patients as compared to control subjects [59], a recent meta-analysis did not find a significant difference in…”
ResultHaapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129
TH17 cells in development: an updated view of their molecular identity and genetic programming
Dong, C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2295 · Cited by 1,064 · cited 1×
“One of the downstream consequences of IL-6 elevation is the differentiation of native T-helper (Th) lymphocytes into IL-17 producing Th17 lymphocytes, thus promoting secretion of IL-17 [53].”
BackgroundBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 2×
“Hence, the current clinical practice continues to be a trial-and-error process that necessitates multiple treatment trials to attain adequate symptomatic control for a majority of patients [20,21].”
BackgroundSelf-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“In fact, over 35% of depressed patients fail to respond to two or more adequate courses of antidepressant medications [20,21,26], i.”
BackgroundSelf-citationCRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.004 · Cited by 972 · cited 1×
“Higher levels of both CRP and IL-6 have also been shown to predict subsequent depressive symptoms [51].”
BackgroundInflammation: Depression Fans the Flames and Feasts on the Heat
Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020152 · Cited by 844
Hodes, G. E., Pfau, M. L., Leboeuf, M., Golden, S. A., Christoffel, D. J., Bregman, D., Rebusi, N., Heshmati, M., Aleyasin, H., Warren, B. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415191111 · Cited by 692 · cited 1×
“In rodent studies of repeated social defeat stress (RSDS), animals susceptible to stress exhibited increased levels of IL-6 early after exposure to stress as compared to those who were resistant to stress [66].”
BackgroundInflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659 · cited 2×
“reported significant improvement in depressive symptoms with anti-cytokine treatments in patients with chronic inflammatory conditions [99].”
BackgroundInflammation-Induced Anhedonia: Endotoxin Reduces Ventral Striatum Responses to Reward
Eisenberger, N. I., Berkman, E. T., Inagaki, T. K., Rameson, L. T., Mashal, N. M., & Irwin, M. R. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.010 · Cited by 596 · cited 1×
“In humans, injection of LPS is associated with worsening of depressive symptoms and reduction in ventrostriatal reward activity to monetary reward cues [64].”
BackgroundA Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580 · cited 1×
“Additionally, TRD patients report higher rates of suicidality and lower quality of life as compared to treatment responsive depressed patients [27].”
BackgroundCellular mechanisms of IL-17-induced blood-brain barrier disruption
Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., Bechmann, I., Becher, B., Luhmann, H. J., Waisman, A., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-141978 · Cited by 529 · cited 1×
“Peripheral IL-17 binds to the IL-17 receptors on the BBB leading to the generation of reactive oxygen species (ROS), which in turn increase BBB permeability [67].”
BackgroundLindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., & Brundin, L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.030 · Cited by 524 · cited 1×
“Higher levels of IL-6 have also been reported in cerebrospinal fluid of depressed patients [49] as well as in suicide attempters [50] as compared to non-depressed controls.”
ResultElevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73 131 Individuals
Wium-Andersen, M. K., Ørsted, D. D., Nielsen, S. F., & Nordestgaard, B. G. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.102 · Cited by 489
Köhler, C. A., Freitas, T. H., Stubbs, B., Maes, M., Solmi, M., Veronese, N., de Andrade, N. Q., Morris, G., Fernandes, B. S., Brunoni, A. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0632-1 · Cited by 449 · cited 10×
“Hence, Jha et al. recently explored a panel of IL-17, Th1- (IFN-γ and TNF-α), Th2- (Il-4, IL-5, IL-9, and IL-13), and non-T cell-related (IL-1β, IL-1 receptor antagonist, IL-6, IL-8, and macrophage inflammatory protein (MIP) 1 α and β) markers as antidepressant treatment selection biomarkers.”
ResultInfluentialWohleb, E. S., McKim, D. B., Sheridan, J. F., & Godbout, J. P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00447 · Cited by 420
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355 · cited 1×
“This is consistent with the failure to find any significant differences in head-to-head trials of antidepressant medications within or across different classes [19].”
ResultQuality of life assessments in major depressive disorder: a review of the literature
Papakostas, G. I., Petersen, T., Mahal, Y., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2004) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2003.07.004 · Cited by 331 · cited 1×
“Additionally, patients with MDD report significant impairment across multiple domains of life such as work productivity [4], non-work-related day to day activities [5], psychosocial function [6], and quality of life [7].”
BackgroundLeighton, S. P., Nerurkar, L., Krishnadas, R., Johnman, C., Graham, G. J., & Cavanagh, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.205 · Cited by 291
Warner-Schmidt, J. L., Vanover, K. E., Chen, E. Y., Marshall, J. J., & Greengard, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104836108 · Cited by 291
Köhler-Forsberg, O., Buttenschøn, H. N., Tansey, K. E., Maier, W., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., Rietschel, M., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.020 · Cited by 283 · cited 1×
“In a recent report from the Genome-Based Therapeutics Drugs for Depression (GENDEP) study, the association of CRP with depression severity was seen only in women but not men [42].”
BackgroundInflammatory T helper 17 cells promote depression-like behavior in mice
Beurel, E., Harrington, L. E., & Jope, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.021 · Cited by 254
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233
Chen, Y., Jiang, T., Chen, P., Ouyang, J., Xu, G., Zeng, Z., & Sun, Y. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2010.10.029 · Cited by 209
Jha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T., Grannemann, B., Soyombo, A., Mayes, T. L., Rush, A. J., & Trivedi, M. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.01.023 · Cited by 206
Self-citationDepression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial
Arnow, B. A., Blasey, C., Williams, L. M., Palmer, D. M., Rekshan, W., Schatzberg, A. F., Etkin, A., Kulkarni, J., Luther, J. F., & Rush, A. J. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14020181 · Cited by 175 · cited 1×
“Similarly, commonly used clinical subtypes of depression defined by the presence of atypical, melancholic or anxious features have failed to predict any significant difference among currently available antidepressant medications [17,18].”
BackgroundTherapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152 · cited 1×
“The resultant neuroinflammation diverts tetrahydrobiopterin, an essential cofactor of both NOS and tyrosine hydroxylase, away from the conversion of tyrosine to L-3,4-dihydroxyphenylalanine, the rate-limiting step of dopamine synthesis [71].”
BackgroundAnti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
The Depression Treatment Cascade in Primary Care: A Public Health Perspective
Pence, B. W., O’Donnell, J. K., & Gaynes, B. N. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0274-y · Cited by 133 · cited 1×
“To reduce the disability and economic burden associated with MDD and to improve the poor clinical outcomes in clinical practice [10], there is an urgent need to parse through the syndromic and etiological heterogeneity of MDD [11].”
BackgroundThe role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications
Felger, J. C. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_13 · Cited by 115
Griffiths, C. E. M., Fava, M., Miller, A. H., Russell, J., Ball, S. G., Xu, W., Acharya, N., & Rapaport, M. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000479163 · Cited by 115
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111 · cited 1×
“proposed a theoretical model whereby serotonergic antidepressants suppress the Th2-mediated immune response, whereas noradrenergic antidepressants suppress the Th1-mediated immune response [83].”
BackgroundKern, S., Skoog, I., Börjesson-Hanson, A., Blennow, K., Zetterberg, H., Östling, S., Kern, J., Gudmundsson, P., Marlow, T., Rosengren, L., et al. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.006 · Cited by 94
Friedman, E. S., Davis, L. L., Zisook, S., Wisniewski, S. R., Trivedi, M. H., Fava, M., & Rush, A. J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.010 · Cited by 81 · cited 1×
“Clinical factors such as severity of depressive symptoms at baseline [13], onset of MDD before the age of 18 year [14], persistence of index major depressive episode longer than 2 years [15] or the presence of insomnia prior to treatment initiation [16] did not moderate outcomes in reports that compared selective sero…”
ResultSelf-citationJha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T. L., Mayes, T. L., & Trivedi, M. H. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.005 · Cited by 79 · cited 1×
“While depressed patients with elevated IL-17 levels prior to treatment initiation experienced a greater reduction in depression severity with the bupropion-SSRI combination as compared to those with lower IL-17 levels, no such association was seen in SSRI monotherapy and venlafaxine-mirtazapine combination treatment a…”
ResultSelf-citationMcNutt, M. D., Liu, S., Manatunga, A., Royster, E. B., Raison, C. L., Woolwine, B. J., Demetrashvili, M. F., Miller, A. H., & Musselman, D. L. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.330 · Cited by 56 · cited 1×
“results only in the improvement of core mood and not in other symptom domains [35].”
Background
Cited by
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936486 · Cited by 128
“MDD is a heterogeneous disorder and the understanding of its neurobiology is essential for the development of more efficient treatments (Jha and Trivedi, 2018; Mora et al., 2018).”
BackgroundHan, L. K. M., Verhoeven, J. E., Tyrka, A. R., Penninx, B. W. J. H., Wolkowitz, O. M., Månsson, K. N. T., Lindqvist, D., Boks, M. P., Révész, D., Mellon, S. H., et al. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.04.004 · Cited by 104
Ormel (2019) · doi:10.1097/yco.0000000000000505 · Cited by 102
Neuroimmune Advance in Depressive Disorder
Zhao, G., & Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9271-0_4 · Cited by 20
Metadata
- Authors
- Jha, M., & Trivedi, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-01-12
- Volume
- 19
- Issue
- 1
- Pages
- 233
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2783008941
- Cited by
- 86
- References
- 53
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.